VOLUME 17 | NUMBER 5 | MAY 2014 nature neurOSCIenCe a r t I C l e S Astrocytes contribute to the function of neurons and the brain [1] [2] [3] . There is also growing appreciation that astrocytes contribute to neuro logical and psychiatric diseases 2,4-6 . HD is an autosomal dominant disorder characterized by progressive motor, cognitive and psychiatric disturbances associated with neuronal dysfunction and atrophy of the striatum and other brain regions. HD is caused by an expanded chain of polyglutamines localized to the Nterminal region of the huntingtin protein (HTT) that cause intracellular accumulation and aggregation of mutant HTT (mHTT) 7 . The physiological role of HTT and the mechanisms that produce the disease are largely unknown, although intense effort has focused on the study of the effects of mHTT expres sion on neuronal function, particularly in the striatum 8 . Recent studies have suggested that astrocytes may also be involved in HD. Brains from HD patients and from mouse models of HD show accumulation of mHTT in striatal astrocytes 9, 10 . Selective expression of mHTT only in astrocytes leads to cell death of striatal neurons 9 , reduced glutamate transporter expression 10 and agedependent broadly HDlike pathol ogy 11 . However, these studies do not prove that astrocyte physiology is altered in conventional mouse models of HD.
a r t I C l e S
Astrocytes contribute to the function of neurons and the brain [1] [2] [3] . There is also growing appreciation that astrocytes contribute to neuro logical and psychiatric diseases 2, [4] [5] [6] . HD is an autosomal dominant disorder characterized by progressive motor, cognitive and psychiatric disturbances associated with neuronal dysfunction and atrophy of the striatum and other brain regions. HD is caused by an expanded chain of polyglutamines localized to the Nterminal region of the huntingtin protein (HTT) that cause intracellular accumulation and aggregation of mutant HTT (mHTT) 7 . The physiological role of HTT and the mechanisms that produce the disease are largely unknown, although intense effort has focused on the study of the effects of mHTT expres sion on neuronal function, particularly in the striatum 8 . Recent studies have suggested that astrocytes may also be involved in HD. Brains from HD patients and from mouse models of HD show accumulation of mHTT in striatal astrocytes 9, 10 . Selective expression of mHTT only in astrocytes leads to cell death of striatal neurons 9 , reduced glutamate transporter expression 10 and agedependent broadly HDlike pathol ogy 11 . However, these studies do not prove that astrocyte physiology is altered in conventional mouse models of HD.
An appraisal of existing animal models of HD does not reveal that any one is superior 12 , and so we explored astrocyte physiology in two mouse models of HD: the early onset wellestablished 'aggressive' exon 1 human mHTT transgenic R6/2 model 7 and the more slowly developing knockin Q175 model 13, 14 . We found that Kir4.1 potassium ion channel expression was decreased in astrocytes that express mHTT, with little or no evidence for reactive astrogliosis at stages corresponding with initial onset of symptoms in both mouse models. The loss of a resting K + conductance depolarized astrocytes and likely contributed to the elevated levels of K + that we measured in vivo in the striatum of HD model mice. Moreover, we found that these subtly elevated extracellular K + levels (by ~2 mM) depolarized MSNs and increased their excitability. Conversely, rescuing the loss of astrocyte Kir4.1 channels ameliorated several deficits associated with HD mouse models. We propose that some features of MSN dysfunction in HD are secondary to disturbances of astrocyte Kir4.1. Thus, these data reveal astrocytes as potential cellular targets for therapeutic development in HD. a r t I C l e S associated with classical astrogliosis 15 (n = 4 mice, 32 astrocytes; Fig. 1b-e) . Using Ki67 immunostaining, we also found no evidence of astrocyte proliferation in R6/2 mice at P60-80, or even at P110, a time of considerable tissue loss (n = 5 mice; Supplementary Fig. 2 ). pSTAT is a transcriptional regulator that is strongly increased during classical astrogliosis 16 , but we found no evidence for upregulation of pSTAT3 in R6/2 mice at P60-80 (data not shown, n = 4 mice). Finally, using west ern blot analysis of striatal tissue, we found no evidence for increased GFAP expression in R6/2 mice at P60-80 relative to WT littermates (n = 4 mice; Fig. 1f ). In contrast, in older R6/2 mice (P104-110), when overt striatal atrophy and neurodegeneration has occurred, there (e) Quantification of key parameters from Sholl analysis for images such as those shown in c. (f) Western blot analysis of GFAP expression in WT and R6/2 mice. The gels show data for P60 (in duplicate), whereas the bar graph summarizes data at P30 and P60-80 (quantification was achieved by normalizing to β-actin). The data shown in this figure were normally distributed and thus statistical significance was assessed by unpaired Student's t test; P values are shown. For the box and whisker plots, the box is s.e.m. and the whisker is s.d. The bullet represents the mean and the horizontal line through the box is the median. Please also define the mean and median symbols in box and whisker plots. Fig. 3 ).
Our analysis of astrogliosis is consistent with early observations on GFAP expression in R6/2 mice 7 and suggests that HDlike symptoms in the mice occur before overt astrogliosis. In humans, a doubling of GFAP expression is observed in late stages of HD (grades 3 and 4), but no statistically significant differences from control are reported at grade 0 (ref. 10).
Striatal astrocytes display altered properties in HD mice
In contrast with GFAP, which marked only a small number of striatal astrocytes (n = 6 mice; Fig. 1a) , Aldh1L1 (ref. 17) , glutamine synthetase (GS) and S100β marked most striatal astrocytes ( Supplementary  Fig. 4) . Colocalization experiments revealed that all GSexpressing astrocytes also expressed Aldh1L1, and all Aldh1L1expressing astrocytes also expressed S100β (n = 4 mice; Supplementary Fig. 5 ). Next, we used triple color immunohistochemistry to determine whether GFAP, Aldh1L1, GS and S100βexpressing astrocytes contained mHTT nuclear inclusions (Fig. 2a) mEM48 antibody, which recognizes exon 1 of mHTT 18 . We found that the nuclei of GFAP, S100β, GS and Aldh1L1labeled astrocytes all expressed mHTT (n = 4 mice; Fig. 2a) , reminiscent of previous findings 9, 10 . Using morphological and electrophysiologi cal criteria 19 to identify astrocytes in brain slices (Supplementary Fig. 6 ), we found that R6/2 astrocytes were significantly more depo larized than WT astrocytes at P60-80 (resting membrane potentials: WT, −76 ± 0.7 mV, n = 79 cells; R6/2, −71 ± 0.8 mV, n = 67 cells; P < 0.0001 using a twotailed MannWhitney test). These differences were not observed at P30 (n = 53-55 cells, P = 0.794 using a twotailed MannWhitney test; Fig. 2b,c and Supplementary Table 1 ). At these same ages, striatal R6/2 astrocytes displayed significantly lower mem brane conductances (Fig. 2d) and showed higher membrane resistances (n = 53-79 cells, P < 0.0001 using a twotailed MannWhitney test; Fig. 3a-d and Supplementary Table 1 ). There were no significant differences in membrane capacitance at P30 or P60-80 (capacitance was 18-19 pF in each case, data not shown; n = 53-79 cells).
Differences in striatal astrocytes between WT and R6/2 mice at P60-80 did not extend to hippocampal astrocytes from R6/2 and WT mice at P30 and P60-80 (n = 7-11 cells; Supplementary Table 1) . To ascertain whether the differences between WT and R6/2 striatal astrocytes were restricted to the R6/2 mouse model, we repeated all of the electrophysi ology experiments in WT, heterozygous and homozygous Q175 mice at 2-3, 6-7 and 9-12 months of age (n = 11-34 cells; Supplementary Tables 2 and 3). We found that astrocytes from Q175 homozygous and heterozygous mice were also more depolarized and display lower membrane conductances at ages when HDlike symptoms were mani fest, that is, 6-7 months for homozygous mice and 9-12 months for heterozygous mice (n = 11-34 cells; Supplementary Tables 2 and 3 ).
Striatal astrocytes from HD mice display reduced Kir4.1 currents Weakly inwardly rectifying Kir4.1 channels are the predominant K + channels in astrocytes 16, 20, 21 and underlie their negative resting membrane potentials near the potassium equilibrium potential 22 (E K ). We explored the possibility that astrocytes from HD mouse models may display reduced Kir4.1 currents. We measured I/V relations before and during extracellular applications of the Kir4.1 channel blocker Ba 2+ (100 µM), and by subtracting the I/V traces ( Supplementary  Fig. 7 ), we isolated Ba 2+ sensitive Kir4.1 currents, which displayed reversal potentials (E rev ) close to E K (Fig. 3e,f and Supplementary  Fig. 7 ) 23 . We repeated these experiments for WT and R6/2 mice at P30 and P60-80, as well as for WT, heterozygous and homozygous Q175 mice at 2-3, 6-7 and 9-12 months of age (n = 12-24; Fig. 3e,f and Supplementary Tables 1-3 ). We found significant (up to 30%) reductions in Ba 2+ sensitive currents in astrocytes from HDmodel mice (both R6/2 and Q175) at symptomatic ages, but not at ages that were presymptomatic (n = 12-24; Fig. 3e,f and Supplementary  Tables 1-3 ). We also used nortriptyline (NOR, 300 µM), which pref erentially blocks Kir4.1 channels over other inward rectifiers 24, 25 . The use of NOR revealed that Kir4.1 currents were reduced in R6/2 mice relative to WT mice at P60-80 (n = 13, 14; Supplementary Table 4) .
We detected astrocyte electrophysiological changes in the 9-12monthold heterozygous Q175 mouse group. How does this relate to symptoms in these mice? Past work has shown that hetero zygous Q175 mice display substantial behavioral changes at less than 6 months of age 14 . In other tests, however, they display no pheno typic changes even when they are 12 months old, and they don't show decreased body weight until they are ~1 year old 14 (but see ref. 13 ). For the I/V plots, in some cases, the error bars (±s.e.m.) are smaller than the symbols used. In the case of b, d and f, the data were not normally distributed and statistical significance was assessed using the non-parametric two-tailed Mann-Whitney test; P values are indicated. For the box and whisker plots, the box is the s.e.m. and the whisker is the s.d. npg a r t I C l e S Moreover, at a cellular level, MSN properties are altered at different ages. Thus, these mice display a phenotypic spectrum that occurs at different ages 14 . We also make no claim that the astrocyte dysfunction that we observed is the only driver of behavioral and systemic disorder in HD mouse models.
Mechanistic insights on reduced Kir4.1 currents in R6/2 mice We used quantitative PCR (qPCR) to determine whether Kir4.1 (also known as Kcnj10) mRNA levels were decreased in R6/2 striatal tissue relative to WT tissue. Although there was a trend for Kir4.1 mRNA levels to be ~10% lower, this did not reach statistical significance (n = 7, 5; P = 0.1688, unpaired Student's t test; Fig. 4a ). Consistent with our western blot data (Fig. 1g) , we found that Gfap mRNA levels were also not significantly changed in R6/2 mice relative to WT mice (n = 7, 5; P = 0.0845, unpaired Student's t test; Fig. 4b) , and, consistent with past studies 26 , we found that Glt-1 (also known as Slc1a2) mRNA levels were significantly reduced in R6/2 mice (P = 0.0267, unpaired Student's t test; Fig. 4c ). For the aforementioned experiments, Kir4.1 mRNA levels were analyzed in relation to GAPDH, ATP5B and UBC as controls ( Supplementary  Fig. 8a ), as these mRNAs are among the most stable in mouse models of HD 27 . Thus, Kir4.1 mRNA levels were not reduced in R6/2 mice at symptomatic ages (P60-80), a finding that was reproduced with the WT, heterozygous and homozygous Q175 mice aged 10 months (n = 4-5; Supplementary Fig. 8b ). This recalls transcriptome analysis of R6/2 mice at ~P63, but differs from human postmortem analysis, where Kir4.1 mRNAs were subtly reduced in grade 3 stages of HD 28 .
mHTT can affect the function of some intracellular ion channels 29 , prompting us to explore whether mHTT directly affects the function of Kir4.1 channels. To test for this, we determined whether mHTT with 145 polyglutamines (mHTTQ145) affected Kir4.1GFP channel function in HEK293 cells. We measured equally sized total and Ba 2+ sensitive Kir4.1 currents in HEK293 cells expressing Kir4.1 GFP alone or Kir4.1GFP and mHTTQ145 (n = 15-17; Fig. 4d,e) . Controls indicated that mHTTQ145 proteins were expressed in HEK293 cells, implying that mHTTQ145 does not directly affect Kir4.1 ion channel function.
We used western blot analysis to determine whether Kir4.1 protein levels were reduced in striatal tissue (relative to βactin); we used Glt1 as a positive control 11 (Fig. 4c) . Western blot analysis revealed significantly reduced levels of Kir4.1 proteins in striatal tissue from R6/2 mice at P60-80, but not at P30 (n = 4; Fig. 4g ). In addition, Glt1 protein levels were reduced as expected (n = 4; Fig. 4h ). Similar data were gathered for Q175 mice (Supplementary Fig. 9 ). We also found that GS levels were reduced in R6/2 mice at P60-80 (n = 4; Fig. 4g ), but only modestly in relation to the reductions that accom pany astrogliosis 15 . Together, the electrophysiology and western blot data provide compelling evidence (Figs. 3 and 4) for astrocyte Kir4.1 channel dysfunction in HD mouse models. npg a r t I C l e S mHTT expressing astrocytes display reduced Kir4.1 immunostaining Using four color immunohistochemistry (Fig. 5a,b) , we studied astrocyte Kir4.1 expression in single cells in relation to nuclei, mHTT nuclear inclusions and S100β for WT and R6/2 mice at P60-80 (Figs. 3  and 4) . In these experiments, mHTT nuclear inclusions indicate which cells exhibit nuclear mHTT aggregates, but they do not tell us about the larger population of cells that may express soluble mHTT 30 . In WT mice, we observed no nuclear mHTT inclusions and robust expression of Kir4.1 in all S100βpositive astrocytes (n = 6 mice; Fig. 5a,c) . In contrast, in R6/2 mice, we observed strong nuclear mHTT staining in ~10% of S100βpositive astrocytes at P30, with a significant increase to ~20% at P60-80 (Fig. 5b,c) . We quantified Kir4.1 immunostaining in S100βpositive astrocytes and found that astrocytes that were S100β positive and also contained mHTT displayed substantially lower levels of Kir4.1 immunostaining as compared with astrocytes in WT mice or astrocytes that did not contain mHTT inclusions in R6/2 mice (Fig. 5d) . Together, these data indicate that a significant fraction of R6/2 S100βpositive astrocytes (~20%) contain mHTT nuclear inclusions at the age of P60-80, and that these astrocytes display reduced Kir4.1 immunostaining (Fig. 5d) . Why is it that ~20% of S100βpositive astrocytes contained mHTT nuclear inclusions (Fig. 5c) , whereas we detected decreased astro cyte Kir.4.1 currents across a sampling of all recorded astrocytes? First, astrocytes are coupled by gap junctions 31 ; thus, singlecell recordings sample a population of astrocytes. Second, mHTT can exist in a soluble form and also within inclusions. Third, despite intense study, it remains unclear whether the major pathological form is the cytosolic or the nuclear inclusion version of mHTT 30 . To try and explore the cytosolic form of mHTT, we also tested the MW8 antibody, but found that this preferentially labeled inclusions (Supplementary Fig. 10 ). We suggest that many astrocytes may contain soluble forms of mHTT not detected by mEM48 and that these lead to Kir4.1 dysfunction in populations of astrocytes; a subpopulation of these (~20%) contain mHTT nuclear inclusions detectable with mEM48.
Astrocyte deficits are rescued by viral delivery of Kir4.1-GFP Our data strongly suggest that Kir4.1 channel function and expression are compromised in striatal astrocytes from symptomatic HD mouse models. In light of this, we asked whether viral delivery of Kir4.1 would rescue the deficits observed in HD mouse models. Detailed work 32 using AAV2/5 and the gfaABC 1 D promoter to drive astro cyte specific gene expression suggested that 2 weeks after infection would be an ideal time to deliver Kir4.1. Thus, following described methods 32 , we used adenoassociated viruses of the 2/5 serotype (AAV2/5) that preferentially target astrocytes 33, 34 together with the gfaABC 1 D promoter to deliver GFPtagged Kir4.1 channels (Kir4.1GFP) or cytosolic tdTomato as a control (Fig. 6a,b) . After injection at P56, AAV2/5mediated viral transduction led to Kir4.1 and tdTomato expression in S100βpositive astrocytes throughout the striatum (n = 4; Supplementary Fig. 11 ): we estimate that Kir4.1 GFP-expressing astrocytes were present in 83 ± 1% (n = 4) of the striatal volume. Kir4.1GFP was not detected in striatal neurons (data not shown). Moreover, in astrocytes that were mHTTpositive in R6/2 mice (Fig. 6b) , AAV2/5 Kir4.1GFP viruses increased Kir4.1 immu nostaining to mean levels of 15.2 ± 0.9 a.u. of fluorescence intensity (n = 35 cells from 4 mice), which was slightly, but not significantly, greater than the mean 13.4 ± 0.4 a.u. (n = 147 cells from 6 mice) seen in WT mice and was significantly greater than the mean 11.1 ± 0.7 a.u. (n = 52 cells from 6 mice) detected in mHTTpositive astrocytes from untreated R6/2 mice (P = 0.0011 with a twotailed MannWhitney test; Fig. 5d) . Thus, AAV2/5 Kir4.1GFP viruses npg a r t I C l e S restored Kir4.1 immunostaining in astrocytes with mHTT nuclear aggregates to essentially normal levels. The I/V relations of P60-80 R6/2 stri atal astrocytes expressing Kir4.1GFP were restored to levels equivalent to WT mice at P60-80 (Figs. 3c and 6c) , whereas the I/V rela tions of astrocytes expressing tdTomato were the same as noninjected R6/2 mice at P60-80 (Fig. 6c) . Moreover, expression of Kir4.1GFP rescued deficits in astrocyte resting membrane potentials and macroscopic slope conduct ance of R6/2 mice (Figs. 3d and 6d,e) . Finally, Ba 2+ sensitive currents recorded from R6/2 astrocytes at P60-80 in Kir4.1GFP-expressing astrocytes were the same size as those recorded from WT mice, whereas they were smaller and equal in cells expressing tdTomato to those measured in uninjected R6/2 mice (Figs. 3f and 6f-h) .
We also carried out controls with the AAV Kir4.1GFP and tdTo mato viruses. AAV2/5 Kir4.1GFP did not substantially increase total or Ba 2+ sensitive currents in WT astrocytes ( Supplementary  Fig. 12a,b) . Relative to mice that received AAV2/5 tdTomato, those that received Kir.4.1GFP displayed substantial levels of GFPtagged Kir4.1 and elevated levels of total Kir4.1 levels by western blot analysis (Supplementary Fig. 12c,d) . Notably, astrocytes expressing Kir4.1 GFP also displayed elevated levels of Glt1 levels as compared with those expressing tdTomato (Supplementary Fig. 12e ), implying that restoration of Kir4.1 function also rescues additional deficits in R6/2 mice. We evaluated whether AAV2/5mediated delivery of Kir4.1 GFP caused inflammation in relation to WT and R6/2 mice, as well as in relation to R6/2 mice receiving AAV2/5 tdTomato, and found that it did not (Supplementary Fig. 13 ).
Elevated striatal K + levels in R6/2 mice and effects on MSNs One of the proposed functions of astrocyte Kir4.1 channels is to maintain extracellular K + levels 23 . In light of this, we asked whether extracellular K + levels were elevated in the striatum of R6/2 mice at P60-80 relative to WT mice (Fig. 7a) . Using K + selective micro electrodes 22, 35 inserted into the striatum in vivo, we found that K + concentration was significantly elevated from 1.5 ± 0.2 mM (n = 6) in WT mice to 2.9 ± 0.3 mM (n = 5) in R6/2 mice at P60-80 (P = 0.0041, unpaired Student's t test; Fig. 7b ). This increase in R6/2 mice was ameliorated by injecting AAV2/5 Kir4.1GFP (K + concentration was 1.8 ± 0.3 mM; n = 5, P > 0.05 compared with WT, unpaired Student's t test). The doubling of the extracellular K + concentration would lead to a substantial depolarization of E K , hence, this discovery in R6/2 mice would be expected to alter neuronal excitability 36 .
Notably, one of the features of HD mouse models is that MSNs are 3-13 mV more depolarized than MSNs in WT mice 14, 37 . We asked whether a change in striatal K + concentration from 1.5-3.0 mM, as measured in R6/2 mice in vivo (Fig. 7b) , could be sufficient to repro duce this effect in WT mice. If so, this would suggest that a hitherto overlooked underlying initial cause of depolarized MSNs may simply be a change in extracellular K + concentration (Fig. 7b) . We made currentclamp recordings from MSNs in brain slices from WT mice and measured their resting membrane potentials in a bath solution containing 1.5 mM K + , then we switched to 3 mM K + and recorded of Ba 2+ -sensitive currents (h) show that AAV2/5-mediated delivery of Kir4.1-GFP restored Ba 2+ -sensitive currents to levels almost identical to those of WT striatal astrocytes at P60-80. In g, the WT data are re-plotted from Figure 3f for comparison purposes. In the case of d, e and h, the data were normally distributed and statistical significance was assessed using the unpaired Student's t test; P values are indicated. Error bars represent s.e.m. npg a r t I C l e S a significant depolarization of ~6 mV (n = 17, P < 0.0001, paired Student's t test; Fig. 7e,f) . Changing the K + concentration also significantly changed the rheobase (n = 5, P = 0.0032, paired Student's t test; Fig. 7c,d,g ), a change that mimics published differences observed for MSNs between HD mouse models and WT mice 14, 37 . In summary, by subtly elevating the extra cellular K + concentration to the same levels that we measured in R6/2 mice in vivo (Fig. 7a,b) , we were able to phenocopy in WT mice several key MSN properties reported in HD mouse models.
Attenuation of phenotypes in R6/2 mice by delivery of Kir4.1-GFP A salient feature across mouse models of HD is that MSNs display depolarized membrane potentials of up to 12 mV (ref. 8) . We considered the possibility that reducing astrocyte Kir4.1 function with Ba 2+ in WT slices may reveal secondary consequences for MSNs, but this experiment was unfeasible (Supplementary Fig. 14) . We therefore used a different approach to explore how dysfunction of astrocyte Kir4.1 channels in R6/2 mice affected MSNs. We measured deficits in MSN properties in HD mice in relation to WT and then sought to determine whether they could be rescued with AAV2/5 Kir4.1 GFP (Fig. 6) . Recalling past work 8 , we found that MSNs from R6/2 mice were substantially depolarized by ~12 mV, were more excit able and displayed higher membrane resistances compared with WT (n = 13-17; Fig. 7h-j) . Next, we injected R6/2 mice with AAV2/5 Kir4.1GFP or AAV2/5 tdTomato and recorded from MSNs 2 weeks later (n = 19-20; Fig. 7h-j) . We found that MSN properties were improved in mice that had been injected with AAV2/5 Kir4.1GFP as compared with AAV2/5 tdTomato (Fig. 7h-j) . Indeed, in the case of resting membrane potentials, expression of Kir4.1GFP rescued MSNs to WT levels (Fig. 7h) , but the rescue was partial in the case of excitability and membrane resistance (Fig. 7i,j) . The differences in MSN properties observed by delivering Kir4.1GFP channels to striatal astrocytes in R6/2 mice (Fig. 7) suggest that Kir4.1 channels may be promising targets for correcting aspects of MSN dysfunction in HD, which, in the simplest interpretation, appear to involve astrocytes and neurons. It is likely that restoring astrocyte Kir4.1 function restores their homeostatic functions in the striatum, which has beneficial effects on MSNs. In addition, neuronastrocyte contacts can regulate ion channel expression in astrocytes 21 , raising the possibility that neuronal properties may be changed by contacting astrocytes with normal Kir4.1 levels 38 .
We next determined whether bilateral striatal injections of AAV2/5 Kir4.1GFP to recover astrocyte Kir4.1 currents (Fig. 6 ) could lead to attenuation of HD phenotypes in male R6/2 mice. We assayed motor coordination using the rotarod 39 without practice sessions. Although practice can improve rotarod performance, untreated R6/2 mice sometimes seized and died immediately after falling off the rotarod and multiple training sessions would have exacerbated this. We used the paw clasp test (Supplementary Fig. 15 ) to measure dystonia and dyskinesia 7 . We used footprint analysis to evaluate gait. Using these assays, we compared WT with R6/2 mice and R6/2 mice that had received either AAV2/5 Kir4.1GFP or AAV2/5 tdTomato injected bilaterally into the striatum at P56. First, in all of the assays, the R6/2 mice displayed severe deficits relative to WT mice, emphasizing HD phenotypes by P92 (Fig. 8, and Supplementary Fig. 15) . Second, we found that delivery of Kir4.1GFP did not improve HD phenotypes in the rotarod or paw clasp assays (Supplementary Fig. 15 ). Third, using footprint analysis we found that Kir4.1GFP expression improved both stride length and width in R6/2 mice to levels that were better than both untreated R6/2 mice and R6/2 mice injected with AAV2/5 tdTomato (Fig. 8a-c) . Fourth, from a specific set of experiments, when analyzed at ~51 d after injection, most of the R6/2 mice that had received AAV2/5 Kir4.1GFP were alive, but most of the R6/2 mice that had received AAV2/5 tdTomato were dead, as expected for R6/2 mice of this age 40 (P < 0.0063, twosided Fisher's exact test; Fig. 8d) . However, there were no differences in body weight between these groups for dead or living mice (Fig. 8e) . For another In the case of f-j, the data were normally distributed and statistical significance was assessed using the paired (f,g) and unpaired (h-j) Student's t tests; P values are indicated.
For the box and whisker plots, the box is s.e.m. and the whisker is s.d.
npg a r t I C l e S different set of experiments, survival analy sis also confirmed the increased longevity of R6/2 mice injected with AAV2/5 Kir4.1 GFP relative to those with AAV2/5 tdTomato (n = 11 and 10; Fig. 8f ), such that, by 115 d after birth (~60 d after injection), ~80% of the R6/2 mice that had received AAV2/5 Kir4.1 GFP were still alive, whereas, as expected 40 , only 22% of mice that received AAV2/5 tdTomato were still alive (P = 0.0063, two sided Fisher's exact test). This was reflected by an increase in the average lifespan by ~8 d from 98.7 ± 5.7 to 116.5 ± 4.5 d for R6/2 mice that received tdTomato or Kir4.1GFP, respectively (P = 0.0306 with a onetailed unpaired MannWhitney test; Fig. 8f) . Thus, differences observed by delivering Kir4.1GFP channels to striatal astrocytes in R6/2 mice (Fig. 8) suggest that motor phenotypes in HD and HD models are a result of complex, multifactorial mechanisms that are likely to involve dysfunction of multiple cell types.
DISCUSSION
There are eight findings from this study. First, striatal astrocytes from R6/2 mice contained mHTT nuclear inclusions at P60-80, that is, when the mice were symptomatic, but before detectable evidence of astrogliosis. Second, striatal astrocytes from symptomatic R6/2 mice displayed depolarized membrane potentials and lower membrane conductances. Third, striatal astrocyte electrophysiological defects could be accounted for by lower functional expression of Kir4.1 channels and could be recovered by AAV2/5mediated delivery of Kir4.1 to astrocytes. Fourth, extracellular K + buffering was reduced in the brains of R6/2 mice, as evidenced by significantly elevated extracellular K + levels in the striatum at P60-80. Fifth, increasing K + concentrations in brain slices from healthy WT mice reproduced some of the features of altered MSN excitability observed in R6/2 mice. Sixth, all of the key cellular observations with R6/2 model mice were reproduced in the Q175 mice when they were symptomatic, implying that these observations are not restricted to the aggressive R6/2 mouse model of HD. In future studies, many more aspects of astrocyte biochemistry and physiology need to be explored in both HD mouse models to determine whether some phenotypic changes can be detected at presymptomatic stages in the less aggressive Q175 mode. If this were to be the case, then this would provide a basis for choosing one mouse model over the other. Seventh, expression of Kir4.1GFP in astrocytes also rescued some MSN deficits observed in R6/2 mice. Eighth, expression of Kir4.1GFP in striatal astrocytes in vivo attenuated a HDlike motor deficit and prolonged survival in R6/2 mice. When interpreting these findings, it is important to remember that the functional measurements relied on wholecell patch clamp electrophysiology that leads to intracellular dialysis of neurons and astrocytes. The study of HD is a rapidly developing field, but only limited attention has focused on astrocytes and their potential roles. Past studies have shown a disruption of astrocyte Glt1 function 11, [41] [42] [43] in HD mouse models, but we were motivated by the discovery that post mortem specimens from HD patients show mHTT inclusions in striatal astrocytes 9, 10 . Moreover, expression of mHTT in astrocytes lead to the death of cocultured striatal neurons 9 , and expression of mHTT in astrocytes in vivo by employing the GFAP promoter leads to reduced Glt1 expression 10 , agedependent HDlike pathology and premature mortality 11 . By their nature, these studies do not prove that astrocyte physiology is altered in, or if astrocytes contribute to, conventional mouse models of HD. Our aim was to confirm or refute the hypothesis that astrocyte physiology is altered in standard models of HD. Our second aim was to evaluate and provide hypotheses for exploring plausible causative roles of astrocytes in HD.
We found that GFAP did not label the majority of astrocytes in the mouse striatum. On the other hand, Aldh1L1, S100β and GS labeled most striatal astrocytes, recalling past experiences with Aldh1L1 (ref. 17) . In R6/2 mice, mHTT nuclear inclusions were detected at P30 npg a r t I C l e S in ~10% of S100βpositive astrocytes before the onset of symptoms and before detectable neurodegeneration. The astrocyte nuclear load of mHTT inclusions increased with time with the onset and progres sion of symptoms and pathology in both R6/2 and Q175 mice. At a time point concomitant with the onset of symptoms (P60-80), sig nificantly more astrocytes (~20%) displayed mHTT inclusions and exhibited significant reductions in important functional proteins, such as GS, Glt1, S100β and Kir4.1, than at a presymptomatic stage (P30). Singlecell analyses demonstrated a positive relation between the presence of mHTT nuclear inclusions in astrocytes and reduc tions in levels of Kir4.1 immunostaining. In contrast, GFAP levels were not significantly altered at this time (P60-80) and there were no other major phenotypic changes associated with astrocyte reactivity 15 . These findings suggest that mHTT is associated with early intrinsic disruption of the expression of important astrocyte functional proteins (for example, Kir4.1, Glt1), which alters astrocyte function without triggering astrogliosis. If so, later signs of astro gliosis in R6/2 mice at greater than P100 could derive from external cues resulting from increasingly severe local neurodegeneration. These data imply that pursuing therapeutic strategies aimed at early stages of the disease may be useful for correcting functional deficits in astrocytes, with the possibility that subsequent astrogliosis may be reduced. Such approaches may be more fruitful than targeting the mechanisms of astrogliosis, which appears to be a heterogeneous 44, 45 , contextdependent and often protective response to a wide range of disparate insults 15 .
It is well established that, in HD mouse models 8 , MSNs are depo larized by up to ~12 mV, display lower membrane conductances and have lower K + currents 46, 47 . Consistent with the MSN data, using two HD mouse models before and during HDlike symptoms, we found that striatal astrocytes were depolarized by +5 mV and displayed lower membrane conductances by up to 20%. Our results indicate that the underlying cause of both these defects can be attributed to a loss of Kir4.1 functional expression in mHTTexpressing striatal astrocytes. This result has clear implications for understanding HD and other neurological and psychiatric disorders, and speaks to the realization that astrocytes act in partnership with neurons in health and disease 2, 3 . Further mechanistic studies are needed to explore how Kir4.1 function and expression are robustly reduced in HD mouse models, even though mRNA levels did not decrease significantly in our evaluations. One possibility is that mHTT affects the trafficking or processing of Kir4.1 channels.
The loss of Kir4.1 currents in striatal astrocytes predicts reduced spatial K + buffering and higher ambient K + levels in HD mouse models 23 . We tested for this and found that the extracellular K + con centration was doubled in R6/2 mice. This prompted us to explore the effect of increased K + (1.5-3.0 mM) on the properties of MSNs in WT mice. To our surprise, we found that these changes reproduced the excitability features of MSNs described in a variety of HD mouse models 8 . Notably, brainwide astrocytespecific deletion of Kir4.1 channels causes mice to fall over, display hind leg splaying and 'wobble' 48 , features that broadly phenocopy HD motor phenotypes in R6/2 mice 7 . To further explore the relationship between astrocyte Kir4.1 channels and HDlike phenotypes in R6/2 mice, we delivered Kir4.1GFP channels to striatal astrocytes and found that one motor symptom (stride length and width) was attenuated by this approach. It seems unlikely that all motor phenotypes can be recovered by any one striatalspecific intervention, as R6/2 mice have multiple abnormalities. Moreover, we found that MSN membrane properties were also partly recovered by astrocytic expression of Kir4.1GFP. These tantalizing findings strongly support the notion that HDlike phenotypes derive from neuronal dysfunction that also involves astrocyte disturbances, pointing toward Kir4.1 as a promising target to potentially correct some deficits in HD.
To date, research efforts have been focused largely on identifying neuronal mechanisms to account for changes in MSN properties in HD models. Our findings provide compelling evidence for the hypothesis that key aspects of altered MSN excitability in HD are secondary to disturbance of astrocyte maintenance of extracellular K + , which may have secondary consequences for MSNs, such as through glutamate transport. These findings have important implications for therapeutic strategies in HD and suggest that therapeutics that target only disturbances of MSNs are likely to be inadequate or suboptimal in regards to restoring function and ameliorating disease symptoms.
METHODS
Methods and any associated references are available in the online version of the paper. 
